<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2016//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_160101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">27529514</PMID>
        <DateCreated>
            <Year>2016</Year>
            <Month>8</Month>
            <Day>16</Day>
        </DateCreated>
        <DateRevised>
            <Year>2016</Year>
            <Month>8</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-1827</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Aug</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of cancer</Title>
                <ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/bjc.2016.236</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To assess antivascular effects, and evaluate clinically translatable magnetic resonance imaging (MRI) biomarkers of tumour response in vivo, following treatment with vanucizumab, a bispecific human antibody against angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Colo205 colon cancer xenografts were imaged before and 5 days after treatment with a single 10?mg?kg(-1) dose of either vanucizumab, bevacizumab (anti-human VEGF-A), LC06 (anti-murine/human Ang-2) or omalizumab (anti-human IgE control). Volumetric response was assessed using T2-weighted MRI, and diffusion-weighted, dynamic contrast-enhanced (DCE) and susceptibility contrast MRI used to quantify tumour water diffusivity (apparent diffusion coefficient (ADC), กั 10(6)?mm(2)?s(-1)), vascular perfusion/permeability (K(trans), min(-1)) and fractional blood volume (fBV, %) respectively. Pathological correlates were sought, and preliminary gene expression profiling performed.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Treatment with vanucizumab, bevacizumab or LC06 induced a significant (P&lt;0.01) cytolentic response compared with control. There was no significant change in tumour ADC in any treatment group. Uptake of Gd-DTPA was restricted to the tumour periphery in all post-treatment groups. A significant reduction in tumour K(trans) (P&lt;0.05) and fBV (P&lt;0.01) was determined 5 days after treatment with vanucizumab only. This was associated with a significant (P&lt;0.05) reduction in Hoechst 33342 uptake compared with control. Gene expression profiling identified 20 human genes exclusively regulated by vanucizumab, 6 of which are known to be involved in vasculogenesis and angiogenesis.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Vanucizumab is a promising antitumour and antiangiogenic treatment, whose antivascular activity can be monitored using DCE and susceptibility contrast MRI. Differential gene expression in vanucizumab-treated tumours is regulated by the combined effect of Ang-2 and VEGF-A inhibition.British Journal of Cancer advance online publication 16 August 2016; doi:10.1038/bjc.2016.236 www.bjcancer.com.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Baker</LastName>
                    <ForeName>Lauren Cj</ForeName>
                    <Initials>LC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Boult</LastName>
                    <ForeName>Jessica Kr</ForeName>
                    <Initials>JK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Thomas</LastName>
                    <ForeName>Markus</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg DE-82377, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Koehler</LastName>
                    <ForeName>Astrid</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg DE-82377, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Nayak</LastName>
                    <ForeName>Tapan</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Roche pRED, Roche Innovation Center, Basel CH-4070, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Tessier</LastName>
                    <ForeName>Jean</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Roche pRED, Roche Innovation Center, Basel CH-4070, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Ooi</LastName>
                    <ForeName>Chia-Huey</ForeName>
                    <Initials>CH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg DE-82377, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Birzele</LastName>
                    <ForeName>Fabian</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg DE-82377, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Belousov</LastName>
                    <ForeName>Anton</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Roche Pharma Research and Early Development (pRED), Roche Innovation Center, Penzberg DE-82377, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Zajac</LastName>
                    <ForeName>Magdalena</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Roche pRED, Roche Innovation Center, Welwyn AL7 1TW, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Horn</LastName>
                    <ForeName>Carsten</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Roche pRED, Roche Innovation Center, Basel CH-4070, Switzerland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>LeFave</LastName>
                    <ForeName>Clare</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Roche pRED, Roche Innovation Center, New York, NY 10016, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author>
                    <LastName>Robinson</LastName>
                    <ForeName>Simon P</ForeName>
                    <Initials>SP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType UI="">JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Br J Cancer</MedlineTA>
            <NlmUniqueID>0370635</NlmUniqueID>
            <ISSNLinking>0007-0920</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>6</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>7</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>8</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">bjc2016236</ArticleId>
            <ArticleId IdType="doi">10.1038/bjc.2016.236</ArticleId>
            <ArticleId IdType="pubmed">27529514</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
